Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash from Financing Activities (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Cash from Financing Activities for 7 consecutive years, with $573.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 2530.21% year-over-year to $573.8 million, compared with a TTM value of $617.5 million through Dec 2025, up 61.99%, and an annual FY2025 reading of $617.5 million, up 61.99% over the prior year.
  • Cash from Financing Activities was $573.8 million for Q4 2025 at Summit Therapeutics, up from $33.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $573.8 million in Q4 2025 and bottomed at -$23.6 million in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $93.9 million, with a median of $20.1 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities skyrocketed 1863133.33% in 2021, then crashed 477.67% in 2024.
  • Year by year, Cash from Financing Activities stood at $1.3 million in 2021, then surged by 41141.87% to $520.1 million in 2022, then tumbled by 98.8% to $6.3 million in 2023, then plummeted by 477.67% to -$23.6 million in 2024, then skyrocketed by 2530.21% to $573.8 million in 2025.
  • Business Quant data shows Cash from Financing Activities for SMMT at $573.8 million in Q4 2025, $33.8 million in Q3 2025, and $2.2 million in Q2 2025.